GlassScriptPhysician profile
Gavin F Brown
NPI 1710164975
$66,805.05
in general payments reported to CMS, 2019-2025
59 companies · $34K in 2025
The $34K reported for 2025 was more than what 95% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,079 · 2020: $183 · 2021: $556 · 2022: $17K · 2023: $3,245 · 2024: $10K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $33K · Consulting Fee: $9,080 · Food and Beverage: $4,634 · Travel and Lodging: $699 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $33,087.50 |
| Consulting Fee | $9,080.00 |
| Food and Beverage | $4,634.04 |
| Travel and Lodging | $698.90 |
| Education | $134.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $34,100.59 | 2019-2025 | Ultomiris |
| Ucb, INC. | $10,761.80 | 2019-2025 | Rystiggo, Zilbrysq, Nayzilam |
| Argenx US, INC. | $8,512.90 | 2022-2025 | Vyvgart Hytrulo |
| Lilly USA, LLC | $4,644.44 | 2025 | Kisunla, Amyvid |
| Janssen Biotech, INC. | $2,319.00 | 2025 | |
| Abbvie INC. | $1,056.55 | 2021-2025 | Qulipta, Botox, Ubrelvy |
| Mdd US Operations, LLC | $545.61 | 2021-2024 | Gocovri, Gocovri |
| Pfizer INC. | $470.73 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $448.44 | 2019-2025 | |
| Celgene Corporation | $429.41 | 2022-2025 | Zeposia |
| Genentech USA, INC. | $351.53 | 2019-2025 | Evrysdi, Ocrevus Zunovo, Ocrevus |
| Biogen, INC. | $344.06 | 2019-2025 | Tysabri, Vumerity, Avonex |
| Supernus Pharmaceuticals, INC. | $208.19 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $184.47 | 2023-2025 | Rexulti |
| Acadia Pharmaceuticals INC | $178.36 | 2019-2025 | Nuplazid |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gavin Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.